Icahn Enterprises LP (NYSE: IEP) is perhaps known more for its billionaire owner/founder Carl Icahn more than it is for its staff, team efforts, and even the enterprise’s name. Icahn’s investment vehicle…
These are some of the key analyst downgrades and negative analyst calls we have seen early this Monday morning with over 2 hours to open: Biogen Idec (BIIB) Cut to Sell at…
Carl Icahn has evolved over the years, first rising to fame a "corporate raider", followed by an ill-fated journey into actual management at the helm of TWA and, most recently, as a…
Douglas A. McIntyre Elan Corporation (ELN) Problems with one of the company’s major drugs. Falls to $9.55 from 52-week high of $37.45. Gatehouse (GHS) More poor newspaper earnings raise issue of whether company is viable.…
This morning’s share price reaction seen in Biogen-Idec Inc. (NASDAQ: BIIB) and Elan Corp. plc (NYSE: ELN) is severe. We do not want to try to sound as though this TYSABRI news…
Douglas A. McIntyre Genentech Inc. (NYSE: DNA) is set to report earnings after the close of trading today. The largest biotech in the U.S. is expected to post $0.86 EPS on $3.23 Billion in revenues…
Douglas A. McIntyre There was interesting event in a 13D filing today right after the close, and that will be worth some news and gossip alike. An investment firm called Amalgamated Gadget LP, which is…
Douglas A. McIntyre Carl Icahn is a billionaire financier, activist, and investor. Most think of Icahn as an activist investor that wants to get inside and drive value without having to acquire the whole company…
Genentech, Inc. (NYSE:DNA) and Biogen Idec, Inc. (Nasdaq:BIIB) came out this morning with some disappointing news. The biotech giants have announced that a Phase II/III study of Rituxan for lupus has failed…
Douglas A. McIntyre Biogen Idec (NASDAQ: BIIB) is sliding marginally despite reported earnings today that showed a 23% increase in earnings riding on sales growth on Avonex and Rituxan. The earnings beat estimates and the…
Thursday after the close, we’ll get to see earnings out of Genentech (NASDAQ: DNA). The estimates from First Call are $0.82 EPS on $3.11 billion in revenues. Next quarter estimates are $0.86…
Many biotech stocks are enjoying large gains Monday, although some are on no real breaking news. Here is a look at some notable gainers: Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) up $1.39 to…
Billionaire activist investor and financier Carl Icahn has released the total holdings in an SEC filing for the period end December 31, 2007 for ICAHN CAPITAL, LP. As Carl Icahn and his…
On Wednesday, we’ll get to see earnings out of Biogen Idec Inc. (NASDAQ: BIIB). The estimates from First Call for the biotech company are $0.80 EPS on $835.16 million in revenues. Estimates…
Douglas A. McIntyre Acorda Therapeutics inc. (NASDAQ: ACOR) showed late stage trial results on its drug candidate Fampridine-SR for treating multiple sclerosis. This data showed that Fampridine, which is designed to treat multiple sclerosis, did…
